Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study

Investigational New Drugs

Volumn 25, Issue 2, 2007, Pages 173-180

  Von Delius, Stefan ^a   Eckel, Florian ^a   Wagenpfeil, Stefan ^b   Mayr, Martina ^a   Stock, Konrad ^a   Kullmann, Frank ^c   Obermeier, Florian ^c   Erdmann, Johannes ^a   Schmelz, Renate ^a   Quasthoff, Stefan ^d   Adelsberger, Helmuth ^a   Bredenkamp, Rainer ^a   Schmid, Roland M ^a   Lersch, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

Carbamazepine; Colorectal cancer; Neurotoxicity; Oxaliplatin; Randomised clinical trial

Indexed keywords

CARBAMAZEPINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TENDON REFLEX; UNSPECIFIED SIDE EFFECT; VIBRATION SENSE; VISUAL HALLUCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; CARBAMAZEPINE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 33845890019     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9010-y     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476-487
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
4. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60(4):895-924
5. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406(1):25-32
6. Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46(2):342-351
7. Luo FR, Wyrick SD, Chaney SG (1999) Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44(1):29-38
8. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5 (Suppl 1):S38-S46
9. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C (2002) [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study] Dtsch Med Wochenschr 127(3):78-82
10. Levi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatori multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900
11. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478-3483
12. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7):1767-1774
13. Schmelz R, Lersch C (2002) Acute oxaliplatin-induced peripheral-nerve hyperexcitability. J Clin Oncol 20(16):3561-3562
14. Rougier P, Lepere C (2005) Second-line treatment of patients with metastatic colorectal cancer. Semin Oncol 32(6 Suppl 9):S48-S54
15. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W (2001) Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12(3):421-422
16. Gedlicka C, Scheithauer W, Schull B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359-3361
17. Durand JP, Brezault C, Goldwasser F (2003) Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 14(6):423-425
18. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055-4061
19. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP, Chiou TJ (2006) N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 1:1-4
20. Susman E (2006) Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 7(4):288